These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 30686091)
41. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Adams A; Lehman TJ Curr Opin Rheumatol; 2005 Sep; 17(5):612-6. PubMed ID: 16093841 [TBL] [Abstract][Full Text] [Related]
42. Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis. Ter Haar NM; Tak T; Mokry M; Scholman RC; Meerding JM; de Jager W; Verwoerd A; Foell D; Vogl T; Roth J; Leliefeld PHC; van Loosdregt J; Koenderman L; Vastert SJ; de Roock S Arthritis Rheumatol; 2018 Jun; 70(6):943-956. PubMed ID: 29426067 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886 [TBL] [Abstract][Full Text] [Related]
44. Pathogenesis of juvenile idiopathic arthritis associated uveitis: the known and unknown. Kalinina Ayuso V; Makhotkina N; van Tent-Hoeve M; de Groot-Mijnes JD; Wulffraat NM; Rothova A; de Boer JH Surv Ophthalmol; 2014; 59(5):517-31. PubMed ID: 25130893 [TBL] [Abstract][Full Text] [Related]
45. [IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions]. Tanaka T Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):433-42. PubMed ID: 27118330 [TBL] [Abstract][Full Text] [Related]
46. Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab. Shimizu M; Ueno K; Yachie A Clin Vaccine Immunol; 2012 Oct; 19(10):1700-2. PubMed ID: 22875602 [TBL] [Abstract][Full Text] [Related]
55. Canakinumab for the treatment of systemic juvenile idiopathic arthritis. Grom AA Expert Rev Clin Immunol; 2014 Nov; 10(11):1427-35. PubMed ID: 25269376 [TBL] [Abstract][Full Text] [Related]
56. Update on the pathogenesis and treatment of systemic idiopathic arthritis. Sikora KA; Grom AA Curr Opin Pediatr; 2011 Dec; 23(6):640-6. PubMed ID: 22045308 [TBL] [Abstract][Full Text] [Related]
57. [Cytokine profile changes in children with juvenile idiopathic arthritis-associated uveitis]. Drozdova EA; Yadykina EV; Mezentseva EA; Nikushkina KV Vestn Oftalmol; 2017; 133(1):27-31. PubMed ID: 28291196 [TBL] [Abstract][Full Text] [Related]
58. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240 [TBL] [Abstract][Full Text] [Related]
59. Tocilizumab and adalimumab in an 18q deletion syndrome patient with chronic arthritis. Kashima S; Tsuchida S; Koizumi H Clin Exp Rheumatol; 2015; 33(1):130-1. PubMed ID: 25665051 [No Abstract] [Full Text] [Related]
60. [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)]. Horneff G Z Rheumatol; 2005 Jun; 64(5):317-26. PubMed ID: 15965816 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]